by novabioticsadm1n | Nov 1, 2021 | 2021, Press Releases
by Paul McIntosh | Oct 29, 2021 | 2021, Press Releases | 0 comments Highlights new insights into cysteamine’s mechanism of action against Pseudomonas aeruginosa and Burkholderia cenocepacia, further supporting cysteamine’s potential as an antimicrobial intervention in...
by novabioticsadm1n | Oct 5, 2021 | 2021, Press Releases
Highlights potential of novel antifungal’s immune-based approach to inhibit fungal pathogens Aberdeen, October 5, 2021. NovaBiotics Ltd, a privately held clinical stage company developing novel immune based therapies for life-threatening and life-limiting diseases,...
by novabioticsadm1n | Sep 23, 2021 | 2021, Press Releases
This new data further supports the potential of NM001 against the most clinically challenging bacterial pathogens, including Pseudomonas aeruginosa, in respiratory disease. NM001 is a registration study-ready candidate intervention (acute use) for pulmonary...
by novabioticsadm1n | Aug 25, 2021 | 2021, Press Releases
Aberdeen, August 24, 2021. NovaBiotics Ltd, a privately held clinical stage company developing novel immune based therapies for life-threatening and life-limiting diseases, announces that Deborah O’Neil, Ph.D., Chief Executive Officer of NovaBiotics, delivered a...
by novabioticsadm1n | Aug 2, 2021 | 2021, Press Releases
Highlights proprietary peptide platform and immune-based approach with manifold therapeutic advantages over traditional drug classes to combat life-threatening fungal and bacterial infectious diseases Aberdeen, August 2, 2021. NovaBiotics Ltd, a privately held...
by Paul McIntosh | Jul 7, 2021 | 2021, Press Releases
NovaBiotics were highlighted in Jonathan Smith’s article in Labiotech on “Scotland’s Top Ten Biotech Companies to Watch Out For.” Learn more about Scotland’s “thriving life sciences ecosystem” by accessing the article Labiotech Article Scotland’s Top Ten...
Recent Comments